Denmark was Genmab A’s largest region in fiscal 2025, bringing in $3.33B of $3.72B (89%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Denmark | $2.33B | $2.87B | $3.33B | |||
| United States | $55.00M | $131.00M | $180.00M | |||
| Japan | $6.00M | $122.00M | $213.00M | |||
| Netherlands | — | — | $1.00M | |||
| Total | $2.39B | $3.12B | $3.72B |
Genmab A brought in $3.72B from its four regions in fiscal 2025, the year ended December 31, 2025. Genmab A regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $3.12B. Denmark was the largest at $3.33B (89.4%), ahead of Japan at $213.00M (5.7%) and United States at $180.00M (4.8%). The remaining region, Netherlands, brought in $1.00M.
Compared with fiscal 2024, Japan grew fastest, up 74.6% to $213.00M. Every region above 2% of revenue grew.
Genmab A began breaking out Netherlands in fiscal 2025, when it brought in $1.00M.
Royalties was Genmab A’s largest revenue line in fiscal 2025, bringing in $3.10B of $3.72B (83%).
| The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table. | FY 2017 | FY 2018 | FY 2019 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Royalties | $1.99B | $2.52B | $3.10B | |||
| Milestone Payments | — | — | — | |||
| Net Product Sales | $61.00M | $253.00M | $398.00M | |||
| Reimbursement Income | — | — | — | |||
| License Fees | — | — | — | |||
| Milestone Revenue | $171.00M | $145.00M | $97.00M | |||
| Reimbursement Revenue | $124.00M | $144.00M | $53.00M | |||
| Collaboration Revenue | $45.00M | $62.00M | $70.00M | |||
| Total | $2.39B | $3.12B | $3.72B |
Genmab A brought in $3.72B from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 19.2% from $3.12B in fiscal 2024. Royalties was the largest at $3.10B (83.4%), ahead of Net Product Sales at $398.00M (10.7%) and Milestone Revenue at $97.00M (2.6%). The other two revenue lines brought in $123.00M combined.
Compared with fiscal 2024, Net Product Sales grew fastest, up 57.3% to $398.00M, while Milestone Revenue fell the most, down 33.1% to $97.00M. From fiscal 2023 to 2025, combined revenue from these revenue lines grew from $2.39B to $3.72B, a compound annual growth rate of 24.8%. Royalties' share held steady at about 83.4%.
Janssen (Darzalex/Daratumumab & Duobody) was Genmab A’s largest revenue line in fiscal 2019, bringing in $4.98B of $5.37B (93%).
| Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|
| Janssen (Darzalex/Daratumumab & Duobody) | $2.21B | $2.39B | $4.98B |
| Other Collaboration Partners | $103.00M | $297.00M | $360.00M |
| Novartis (Arzaerra/Ofatumumab) | $48.00M | $338.00M | $23.00M |
| Total | $2.37B | $3.03B | $5.37B |
Genmab A brought in $5.37B from its three revenue lines in fiscal 2019, the year ended December 31, 2019. That was up 77.4% from $3.03B in fiscal 2018. Janssen (Darzalex/Daratumumab & Duobody) was the largest at $4.98B (92.9%), ahead of Other Collaboration Partners at $360.00M (6.7%) and Novartis (Arzaerra/Ofatumumab) at $23.00M (0.4%).
Compared with fiscal 2018, Janssen (Darzalex/Daratumumab & Duobody) grew 108.5% to $4.98B and Other Collaboration Partners grew 21.2% to $360.00M. From fiscal 2017 to 2019, combined revenue from these revenue lines grew from $2.37B to $5.37B, a compound annual growth rate of 50.6%. Janssen (Darzalex/Daratumumab & Duobody)'s share of the total fell from 93.6% to 92.9%.
Genmab A (GMAB) reports its revenue by geography, by the axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table. and by information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.. In fiscal 2025, Denmark was its largest region, bringing in $3.33B (89.4% of the total), followed by Japan at $213.00M (5.7%).
Denmark was Genmab A's largest region in fiscal 2025, bringing in $3.33B, or 89.4% of the $3.72B total across its four regions.
Royalties was Genmab A's largest revenue line in fiscal 2025, bringing in $3.10B, or 83.4% of the $3.72B total across its five revenue lines.
Among Genmab A's revenue lines that make up at least 2% of revenue, Net Product Sales grew fastest in fiscal 2025, up 57.3% from $253.00M to $398.00M.
Every figure comes from Genmab A's annual financial filings, as reported. Each line keeps the name Genmab A gives it, and years follow its fiscal calendar.
Genmab A's revenue by geography goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.